Receive information and updates on ESMO’s scientific and educational resources, events, members activities. Concise summaries and expert physician commentary that busy clinicians need to enhance patient care. 20. S3C). * Data are shown for adverse events that occurred in at least 10% of the patients in either trial group (except where noted) during the trial intervention or up to 30 days after discontinuation of the intervention. All efficacy data were summarized and analyzed in the intention-to-treat population, which included all the patients who had undergone randomization, regardless of the intervention received. Grade 1 or 2 pneumonitis, interstitial lung disease, or bronchiolitis occurred in 6 patients (1%) in the olaparib group and no patients in the placebo group. View the profiles of people named Paula VS. Join Facebook to connect with Paula VS and others you may know. Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group study. Anticancer Agents; Gynaecological Malignancies, Breakthrough from PAOLA1 GINECO/ENgOT-ov25 trial: Adding Olaparib to Bevacizumab Maintenance Demonstrates Substantial Clinical Benefit in Newly Diagnosed Advanced Ovarian Cancer, Progression-free survival was significantly increased with olaparib plus bevacizumab as maintenance therapy overall and across prespecified subgroups, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals, Collaborating on registries, studies and surveys, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Translational Research and Precision Medicine Working Group, Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group. Eligible patients were 18 years of age or older and had newly diagnosed advanced (International Federation of Gynecology and Obstetrics [FIGO] stage III or IV), high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer. 24. The median duration of follow-up for the primary analysis was 22.7 months (range, 18.0 to 27.7) in the olaparib group and 24.0 months (range, 18.7 to 27.7) in the placebo group; the median duration of follow-up in the combined groups was 22.9 months. The change from baseline in the global health status–quality of life score was assessed with the use of a mixed model for repeated measures.21 Adverse events were analyzed descriptively; an interim safety analysis was planned and conducted. Adverse Events with Olaparib or Placebo in Patients Also Receiving Bevacizumab. The PFS benefit in subgroups of patients with tumour BRCA mutation and in patients that were HRD-positive was substantial. † Eastern Cooperative Oncology Group (ECOG) performance status ranges from 0 to 5, with higher values reflecting greater disability. Live telecast: USA - NBC / Tennis Channel | India - Star Sports / Disney+ Hotstar VIP, Also check out: The Complete French Open 2020 Schedule. The effect of combining maintenance olaparib and bevacizumab in patients regardless of BRCA mutation status is unknown. — all in Madrid; Medical University of Innsbruck, University Clinic for Gynecology and Obstetrics (R.B. An HRD score of 42 or higher indicated a positive test, and an HRD score of less than 42 indicated a negative test.